Do pulmonary hypertension (PHTN) and left atrial enlargement (LAE) classify a patient as having Stage B heart failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Pulmonary hypertension (PHTN) and left atrial enlargement (LAE) alone do not automatically classify a patient as having Stage B heart failure. Stage B heart failure specifically refers to patients who have structural heart disease but have never developed heart failure symptoms. While both PHTN and LAE represent structural or functional cardiac abnormalities, the classification depends on the underlying cause and context. PHTN can occur due to various conditions including left heart disease, lung disease, or primary pulmonary arterial hypertension. Similarly, LAE often develops as a consequence of pressure or volume overload, such as from mitral valve disease or chronic hypertension. For a Stage B heart failure diagnosis, there should be evidence of left ventricular structural changes (like left ventricular hypertrophy or reduced ejection fraction) or previous myocardial infarction. Patients with PHTN and LAE should undergo comprehensive cardiac evaluation including echocardiography, assessment of left ventricular function, and evaluation for underlying causes. Management focuses on treating the underlying condition and implementing preventive strategies including blood pressure control, potentially ACE inhibitors or ARBs, and beta-blockers when appropriate to prevent progression to symptomatic heart failure, as recommended by the American College of Cardiology Foundation and American Heart Association guidelines 1. It is essential to note that the presence of PHTN and LAE may indicate an increased risk of developing heart failure, and therefore, close monitoring and management of these conditions are crucial to prevent progression to symptomatic heart failure. The use of ACE inhibitors and beta-blockers has been shown to be effective in preventing the progression of heart failure in patients with structural heart disease, as demonstrated in several studies 1. In addition, the management of PHTN and LAE should be tailored to the underlying cause and may involve the use of specific therapies such as pulmonary vasodilators or diuretics. Overall, the diagnosis and management of Stage B heart failure require a comprehensive approach that takes into account the underlying cause of the structural heart disease and the presence of any comorbid conditions.

Some key points to consider in the management of patients with PHTN and LAE include:

  • Comprehensive cardiac evaluation including echocardiography and assessment of left ventricular function
  • Evaluation for underlying causes of PHTN and LAE
  • Implementation of preventive strategies including blood pressure control, ACE inhibitors or ARBs, and beta-blockers
  • Close monitoring for signs and symptoms of heart failure
  • Tailored management of PHTN and LAE based on the underlying cause
  • Consideration of the use of specific therapies such as pulmonary vasodilators or diuretics. The American College of Cardiology Foundation and American Heart Association guidelines provide a framework for the diagnosis and management of heart failure, including Stage B heart failure 1. It is essential to stay up-to-date with the latest guidelines and recommendations to provide optimal care for patients with heart failure. In patients with stage B heart failure, the use of ACE inhibitors and beta-blockers has been shown to reduce the risk of progression to symptomatic heart failure and improve outcomes, as demonstrated in several studies 1. The management of PHTN and LAE should be individualized based on the underlying cause and the presence of any comorbid conditions. Overall, the diagnosis and management of Stage B heart failure require a comprehensive approach that takes into account the underlying cause of the structural heart disease and the presence of any comorbid conditions.

From the Research

Classification of Heart Failure

  • Stage B heart failure is characterized by the presence of structural heart disease without symptoms of heart failure [(2,3,4,5)].
  • Pulmonary hypertension (PHTN) and left atrial enlargement (LAE) are conditions that can be associated with heart failure [(2,3,4,5)].

Relationship between PHTN, LAE, and Stage B Heart Failure

  • PHTN due to left heart disease is the most common type of PHTN and is defined as mean pulmonary artery systolic pressure of >20 mm Hg and pulmonary capillary wedge pressure >15 mm Hg during right heart catheterization 3.
  • LAE can be a cause of PHTN due to elevated left atrial pressure [(3,4)].
  • The presence of PHTN and LAE can be indicative of underlying left heart disease, which can classify a patient as having Stage B heart failure [(2,3,4,5)].

Diagnostic Considerations

  • Transthoracic echocardiography can be used to estimate the probability of PHTN and assess left atrial size [(2,6)].
  • Right-sided heart catheterization is essential for accurate diagnosis and classification of PHTN 2.
  • Hemodynamic measures such as diastolic pressure gradient, transpulmonary gradient, and pulmonary vascular resistance can assist in differentiating pre- from postcapillary PHTN [(3,5)].

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pulmonary Hypertension: A Brief Guide for Clinicians.

Mayo Clinic proceedings, 2020

Research

Pulmonary Hypertension in Left Heart Disease.

Clinics in chest medicine, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.